 Cardiovascular Agents
"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
| Descriptor ID |
D002317
|
| MeSH Number(s) |
D27.505.954.411
|
| Concept/Terms |
Cardiovascular Agents- Cardiovascular Agents
- Agents, Cardiovascular
- Cardiovascular Drugs
- Drugs, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".
This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 2 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 4 | 5 | | 2010 | 0 | 3 | 3 | | 2011 | 4 | 2 | 6 | | 2012 | 1 | 4 | 5 | | 2013 | 2 | 0 | 2 | | 2014 | 6 | 1 | 7 | | 2015 | 7 | 2 | 9 | | 2016 | 8 | 2 | 10 | | 2017 | 6 | 2 | 8 | | 2018 | 5 | 4 | 9 | | 2019 | 5 | 0 | 5 | | 2020 | 1 | 1 | 2 | | 2021 | 3 | 1 | 4 | | 2022 | 3 | 0 | 3 | | 2023 | 3 | 1 | 4 | | 2024 | 2 | 2 | 4 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, Berning AA, Minobe WA, Carroll IA, Jonas ER, Slavov D, Emani S, Abraham WT, Gollah AR, Ellis SL, Taylor MRG, Graw SL, Mestroni L, McKinsey TA, Buttrick PM, Kao DP, Bristow MR. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circ Heart Fail. 2025 Apr; 18(4):e012484.
-
Ho PM, Glorioso TJ, Allen LA, Blankenhorn R, Glasgow RE, Grunwald GK, Khanna A, Magid DJ, Marrs JC, Novins-Montague S, Orlando S, Peterson P, Plomondon ME, Sandy LM, Saseen JJ, Trinkley KE, Vaughn S, Waughtal J, Bull S. Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications: A Randomized Pragmatic Trial. JAMA. 2025 01 07; 333(1):49-59.
-
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 Dec 17; 13(24):e036998.
-
Dickert NW, Speight CD, Balser M, Biermann H, Davis JK, Halpern SD, Ko YA, Krishnan A, Matlock DD, Mitchell AR, Moore MA, Montembeau SC, Morris AA, Noonan K, Rao BR, Scherer LD, Sloan CE, Ubel PA, Allen LA. Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF). Circ Cardiovasc Qual Outcomes. 2025 Jan; 18(1):e011273.
-
Blumer V, Januzzi JL, Lindenfeld J, Solomon SD, Psotka MA, Carson PE, Bristow MR, Abraham WT, Gandotra C, Saville BR, O'Connor C, Fiuzat M. Heart?Failure Drug Development Over?the?Eras: From the Heart?Failure Collaboratory. JACC Heart Fail. 2024 Nov; 12(11):1803-1813.
-
Di Palo KE, Feder S, Baggenstos YT, Cornelio CK, Forman DE, Goyal P, Kwak MJ, McIlvennan CK. Palliative Pharmacotherapy for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circ Cardiovasc Qual Outcomes. 2024 Aug; 17(8):e000131.
-
Salahuddin T, Hebbe A, Daus M, Essien UR, Waldo SW, Rodriguez F, Ho PM, Simons C, Gilmartin HM, Doll JA. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021. Am Heart J. 2024 02; 268:68-79.
-
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Gr?nig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 04 20; 388(16):1478-1490.
-
Swat SA, Hebbe A, Plomondon ME, Park KE, Bricker RS, Waldo SW, Valle JA. Contemporary Management Before Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circ Cardiovasc Qual Outcomes. 2023 03; 16(3):e008949.
-
Shorofsky MJ, Morgan GJ, Mejia E, Rodriguez SA, Greene M, Sheaks P, Ivy D, Zablah JE. Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography. Pediatr Cardiol. 2023 Jun; 44(5):1125-1134.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|